ePrivacy and GPDR Cookie Consent by TermsFeed Generator
Join Us for a Live Webinar on March 29, 2023. Epigenetic Therapy Targets the 3D Epigenome in Breast Cancer |Register Now

Aaron Viny, MD, MS, joins Arima Genomics’ scientific advisory board.

Carlsbad, Calif. – February 13, 2023 – Arima Genomics, Inc., a company leveraging 3D genomics to reveal actionable insights to empower researchers and clinicians seeking to improve human health, today announced the appointment of Aaron Viny, MD, MS, to their scientific advisory board (SAB). As part of the SAB, Dr. Viny, a physician scientist with deep experience in cancer, stem cell biology, and 3D genomics, will advise Arima Genomics on how to best serve the needs of translational researchers studying cancer.

“Dr. Viny was an early adopter of Arima Genomics technology and has since been a tremendous collaborator across many projects,” said Anthony Schmitt, SVP of Science at Arima Genomics. “We look forward to more formally incorporating his unique perspective as a renowned physician scientist into our thinking about advancing the science of cancer biology and ultimately accelerating its incorporation into clinical practice to benefit cancer patients.”

Dr. Aaron Viny is an Assistant Professor of Medicine at Columbia University Vagelos College of Physicians and Surgeons, where he specializes in the care of patients with hematological malignancies, including myelodysplastic syndrome and acute leukemia. In his lab at the Columbia Stem Cell Initiative, he and his team leverage 3D genomics to study gene regulatory programs in normal blood formation and blood cancers, uncover genetic and epigenetic underpinnings of cancer, and optimize treatment options. Dr. Viny received his medical degree at Cleveland Clinic Lerner College of Medicine at Case Western Reserve University. He completed his residency in internal medicine at New York-Presbyterian/Weill Cornell Medical College and his fellowship in hematology and medical oncology at Memorial Sloan Kettering Cancer Center.

“The scientific community has only begun to understand the myriad of genetic and epigenetic factors that lead to the development of cancer and how they can be addressed with therapies and other interventions,” said Dr. Viny. “Emerging genomics tools, including those being developed by Arima Genomics, will play a critical role in advancing our understanding of cancer’s development and helping identify new targets for treating cancers.”

Arima Genomics’ SAB was created in 2017 to provide guidance to the company’s leadership team on future scientific and technical applications of the company’s technology. Dr. Viny joins founding SAB members Bing Ren, PhD, Professor of Cellular and Molecular Medicine at the University of California San Diego Ludwig Institute for Cancer Research, and Job Dekker, PhD, Professor in the Departments of Systems Biology, and Biochemistry & Molecular Biotechnology at University of Massachusetts Chan Medical School.

 

About Arima Genomics

Arima Genomics, Inc. is advancing human health and the life sciences by revealing actionable genomic insights. Researchers and clinicians use Arima Genomics’ innovative products and services to gain unparalleled access to the three-dimensional (3D) organization of the genome. This advanced technology enables exploration of disease mechanisms, the discovery of novel biomarkers and therapeutic targets, and identification of gene fusions to aid in patient management.

 

Contacts

For media
Gwen Gordon
gwen@gwengordonpr.com

For general inquiries
Pamela Bentley Mills, PhD
pamela@arimagenomics.com